Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Expeditors International of Wshngtn Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while Expeditors International of Wshngtn Inc trades at $197.41 (market cap $25.37B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 8.9× Dyne Therapeutics Inc. Common Stock's market cap, and Expeditors International of Wshngtn Inc pays a 0.83% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Expeditors International of Wshngtn Inc for 44 Days on average.
| DYN | EXPD | |
|---|---|---|
Market Cap | $2.86B | $25.37B |
Volume | 3,341,579 | 1,236,812 |
Sector | Health | Industrials |
52-Week High | $26.78 | $196.38 |
52-Week Low | $14.60 | $117.35 |
Typical Hold Time | 0 Days | 44 Days |
Enterprise Value | $2.18B | $24.90B |
Dividend Yield | — | 0.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
EXPD trades at $196.38, up 1.54% today, with a bullish technical signal from moving averages and strong profitability metrics including a 42.6% ROE. Recent quarters show consistent earnings beats, and cash flow improved to a positive $166 million in 2025. News highlights efficiency initiatives and AI's impact on freight markets, supporting positive momentum.
The stock's outlook is mixed; fundamentals are solid with revenue growth to $12.0B projected for 2026, but valuation is elevated at a P/E of 28.4, and analyst consensus is cautious with a $179.43 price target below current levels. Risks include reliance on freight demand cycles and competitive pressures in logistics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
